Clinical Trial Search

Primary: Number of Subjects Reporting Plasmodium Falciparum (P. Falciparum) Parasitemia (Defined by a Positive Blood Slide) Following Sporozoite Challenge (in All Study Groups…

Primary: Percentage of Subjects With at Least One Episode of Shigellosis According to the Protocol Primary Case Definition — 46.9; 42.9 Percentage of subjects — p=0.4266

Primary: Progression Free Survival (PFS) — 53 percentage of participants

Primary: Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate — 67; 70 beats per minutes (BPM) — p=0.004

Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Maximum Tolerated Dose (MTD) of PLX3397 Given in Combination With Standard Dose Eribulin in Participants With Metastatic Breast Cancer (Phase 1b) — 1,000 miligrams per day

Primary: Patients' Safety During Study — 90; 2 Events related to TG01 and /or GM-CSF

Primary: The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to…

Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001

Primary: Optimal Biologic Dose of MEDI-551 for Part A — 12 mg/Kg

Primary: Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve…

Primary: Progression-free Survival in Months — 2.8; 1.6 months

Primary: Number of Participants With Treatment-related Adverse Events — 4; 4; 21; 17 Participants

Primary: Lactobacillus Safety — .594 Adverse Events — p==0.219

Primary: Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy — 40.9; 39.1 percentage of patients